Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

29%

2 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 4

2(50.0%)

N/A

2(50.0%)

4Total

Phase 4(2)

N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT06814210Not ApplicableNot Yet Recruiting

CAP-TEER: CerebrAl Protection During Transcatheter Edge-to-edge Repair

Role: lead

NCT06762145Phase 4Not Yet Recruiting

EArly Effect of Glucocorticoid on Incidence of Persistent Left BundlE Branch Block (LBBB) Post-TAVR (EAGLE-TAVR Trial)

Role: lead

NCT06386016Recruiting

Detection of Valvular Heart Disease Using Artificial Intelligence-based Stethoscope

Role: lead

NCT06259370Not ApplicableCompleted

Benefits of VILPA in Young Adults

Role: lead

NCT06031675Completed

Mechanism for Exercise to Delay Cardiac Aging

Role: lead

NCT02498470Unknown

Prospective Registry to Assess the Cath Lab Percutaneous Coronary Intervention Long-term Outcomes: a Single Center

Role: lead

NCT02299245Phase 4Unknown

Rosuvastatin Effect on Telomere-telomerase System in ACS

Role: lead

All 7 trials loaded